ABSTRACT

The surgical treatment of aortoiliac occlusive disease by aortofemoral or iliofemoral bypasses dates back to the early 1950s; since then, with the emergence of appropriate biomaterials for grafting in the 1960s and the improvement of anesthesiology, the frequency of this surgery gradually increased. The perioperative mortality rate is now of the order of 3.3%, with systemic morbidity varying around 8.3% [1]. Long-term patency rates are good. For claudication, the 5-year patency rate of aortobifemoral bypass (AFB) varies from 87.5-91%; at 10 years, from 81.6-86.8% of the bypasses are patent [1].